Multifunctional antibody therapy for acute myocardial infarction Patients with acute coronary syndrome (ACS) suffer from a range of acute myocardial ischemic states. Thrombolysis and percutaneous intervention (PCI) are used to reperfuse the ischemic tissue and stabilize damage caused by infarction. After acute myocardial infarction (AMI), ischemic tissues undergo cell death from necrosis and apoptosis, followed by inflammation and a process of granulation leading to scar tissue formation. The goal of this project is to minimize the level of cell death that occurs immediately after reperfusion and to rapidly restore damaged vasculature and myocardium by establishing a regenerative extracellular matrix (ECM) environment and chemotactic signals necessary for recruitment and differentiation of endogenous stem/progenitor cells. This approach combines multiple functional domains proven to act independently, that are specifically delivered to ischemic myocardium by antibody targeting. This approach has several advantages, including intravenous delivery of a protein therapeutic, and the ability to dose both immediately after reperfusion as well as periodically thereafter to maintain therapeutic efficacy over the course of recovery. Success in phase 1 of the project will identify a clinical candidate for further development. Phase 2 will focus on the production of clinical grade material and preclinical studies to support filing of an IND for a clinical trial in patients with acute myocardial infarction
Multifunctional antibody therapy for acute myocardial infarction Cardiovascular disease is the leading cause of mortality and morbidity in developed countries. Acute myocardial infarction (AMI) affects 19 million people worldwide, with a large number suffering from heart failure. To goal of this project is to develop a novel antibody-based therapy that will significantly enhance the recovery of heart function early after AMI and thereby greatly reduce the level of mortality while improving quality of life of affected patients.
